Stephen Basil ThomasDirector
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001193125-26-394357
| Transaction | Security | Shares | Price | ValueValue (shares × price) | Held after | Ownership |
|---|---|---|---|---|---|---|
SaleSep 15, 2026 | Common StockF1F2F3 | 100,000 | $13.6682 | $1.37M | 467,969 | Direct |
Filing footnotes · 3
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.